Psoriasis is a chronic, relapsing, immune-based skin disease that affects an estimated 1-3% of the world's population.
There is no consensus regarding the exact etiology of psoriasis; among several postulated pathophysiological causes, excessive activity of T cell-mediated immune response, and T-helper (Th) in particular, is the most accepted theory. This is supported by increased levels of pro-inflammatory cytokines, especially tumor necrosis factor (TNF-α) in the serum, skin lesions and joints of these patients. 2, 3 Although inhibitors of tumor necrosis factor (TNF-α) have been shown to be effective for treating refractory psoriasis, 3, 4 there are no therapies providing long-lasting remission for these patients.
Since Tracey 5 proposed the so-called inflammatory reflex, the data now emerging has been elucidating and supporting the existence of a neural circuit that modulates immune response.
This cholinergic anti-inflammatory pathway originates from efferent vagal fibers. It seems that inhibition of TNF-α production in the spleen following vagal nerve stimulation occurs through acetylcholine signaling via the α7 nicotinic acetylcholine receptor that is expressed on cytokineproducing macrophages. 5, 6 This signal is relayed through an acetylcholine-producing, memory phenotype T cell population that has been identified in mice, which is necessary for inhibition of cytokine production through vagus nerve stimulation. 7 Immunomodulation via vagal nerve stimulation has been implicated in the treatment of other immune disorders involving the TNF-α pathway, such as inflammatory bowel disease. 8 In this regard, we support the hypothesis that vagal nerve stimulation may prove useful for treating refractory psoriasis and psoriatic arthritis through its cholinergic anti-inflammatory effects, by means of modulating TNF-α production. 9 This novel idea encourages interest in conducting a double-blind case-control study to investigate the possible role of vagal nerve stimulation in treating psoriasis and psoriatic arthritis. 
